Alex Ralph
alexralph.bsky.social
Alex Ralph
@alexralph.bsky.social
Chief Business Correspondent @thetimes.com
Interview with new Make UK chairman Lord Harrington on the industrial strategy, FDI and growth

The veteran businessman and politician will have an important role shaping UK industry half a century after watching its decline growing up in Leeds

www.thetimes.com/business-mon...
Make UK’s next chair: ‘Look to our rivals for an industrial strategy’
In the 1960s his father’s shirt factory succumbed to cheaper overseas labour. Now Richard Harrington has a key role in boosting Britain’s manufacturing base
www.thetimes.com
January 22, 2025 at 6:18 PM
Delays in securing government support have led AstraZeneca to miss a key internal deadline on a proposed £450 million investment in a new vaccines facility in Speke, despite the business secretary being warned privately that it was an “urgent issue”

www.thetimes.com/business-mon...
AstraZeneca’s £450m plant hits setback caused by Whitehall delays
Government delays threaten AstraZeneca’s vaccine facility in Speke, jeopardising a key investment and raising questions about the UK’s commitment to life sciences
www.thetimes.com
January 20, 2025 at 3:41 PM
The administrators of Safe Hands Plans, the pre-paid funerals company whose collapse has left 46,000 customers with a combined £60 million shortfall, have succeeded in appointing liquidators to a Cayman Islands company where customer money was funnelled

www.thetimes.com/article/346c...
Safe Hands administrators appoint Cayman Islands liquidator
FRP says licensed insolvency practitioners have taken control of company where customers’ money was funnelled
www.thetimes.com
January 3, 2025 at 4:38 PM
AstraZeneca, Britain’s most valuable public company, has made about £45 million in payments to doctors and healthcare organisations in Russia since the war against Ukraine, despite the UK’s growing involvement

www.thetimes.com/article/ac81...
AstraZeneca paid £45m to doctors in Russia since war began
Analysis of data by The Times shows that the British pharmaceutical company has made the payments over two years at a time when other multinationals have pulled out of Russia
www.thetimes.com
December 27, 2024 at 8:48 PM